These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35241721)

  • 1. Radiotherapy alters expression of molecular targets in prostate cancer in a fractionation- and time-dependent manner.
    Eke I; Aryankalayil MJ; Bylicky MA; Makinde AY; Liotta L; Calvert V; Petricoin EF; Graves EE; Coleman CN
    Sci Rep; 2022 Mar; 12(1):3500. PubMed ID: 35241721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term expression changes of immune-related genes in prostate cancer after radiotherapy.
    Eke I; Aryankalayil MJ; Bylicky MA; Sandfort V; Vanpouille-Box C; Nandagopal S; Graves EE; Giaccia AJ; Coleman CN
    Cancer Immunol Immunother; 2022 Apr; 71(4):839-850. PubMed ID: 34435232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Tumor Adaptation after Radiotherapy: Therapeutic Implications for Targeting Integrins in Prostate Cancer.
    Eke I; Makinde AY; Aryankalayil MJ; Reedy JL; Citrin DE; Chopra S; Ahmed MM; Coleman CN
    Mol Cancer Res; 2018 Dec; 16(12):1855-1864. PubMed ID: 30042176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fractionated radiation therapy can induce a molecular profile for therapeutic targeting.
    John-Aryankalayil M; Palayoor ST; Cerna D; Simone CB; Falduto MT; Magnuson SR; Coleman CN
    Radiat Res; 2010 Oct; 174(4):446-58. PubMed ID: 20726711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells.
    Aryankalayil MJ; Makinde AY; Gameiro SR; Hodge JW; Rivera-Solis PP; Palayoor ST; Ahmed MM; Coleman CN
    Radiat Res; 2014 Aug; 182(2):139-48. PubMed ID: 25003313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill.
    Bromfield GP; Meng A; Warde P; Bristow RG
    Prostate Cancer Prostatic Dis; 2003; 6(1):73-85. PubMed ID: 12664070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland.
    Mohan DS; Kupelian PA; Willoughby TR
    Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):575-80. PubMed ID: 10701736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [
    Arbuznikova D; Klotsotyra A; Uhlmann L; Domogalla LC; Steinacker N; Mix M; Niedermann G; Spohn SKB; Freitag MT; Grosu AL; Meyer PT; Gratzke C; Eder M; Zamboglou C; Eder AC
    Theranostics; 2024; 14(6):2560-2572. PubMed ID: 38646643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
    Herrera FG; Valerio M; Berthold D; Tawadros T; Meuwly JY; Vallet V; Baumgartner P; Thierry AC; De Bari B; Jichlinski P; Kandalaft L; Coukos G; Harari A; Bourhis J
    Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):320-334. PubMed ID: 30267761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The lncRNAs
    Eke I; Bylicky MA; Sandfort V; Chopra S; Martello S; Graves EE; Coleman CN; Aryankalayil MJ
    Mol Ther Nucleic Acids; 2021 Jun; 24():175-187. PubMed ID: 33767914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palliation of bone metastases: a survey of patterns of practice among Canadian radiation oncologists.
    Chow E; Danjoux C; Wong R; Szumacher E; Franssen E; Fung K; Finkelstein J; Andersson L; Connolly R
    Radiother Oncol; 2000 Sep; 56(3):305-14. PubMed ID: 10974379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
    Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
    Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
    Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
    Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 53BP1/RIF1 signaling promotes cell survival after multifractionated radiotherapy.
    Eke I; Zong D; Aryankalayil MJ; Sandfort V; Bylicky MA; Rath BH; Graves EE; Nussenzweig A; Coleman CN
    Nucleic Acids Res; 2020 Feb; 48(3):1314-1326. PubMed ID: 31822909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.
    Bolla M; Van Tienhoven G; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Billiet I; Torecilla JL; Pfeffer R; Cutajar CL; Van der Kwast T; Collette L
    Lancet Oncol; 2010 Nov; 11(11):1066-73. PubMed ID: 20933466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of elapsed treatment time on outcome of external-beam radiation therapy for localized carcinoma of the prostate.
    Perez CA; Michalski J; Mansur D; Lockett MA
    Cancer J; 2004; 10(6):349-56. PubMed ID: 15701266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR).
    Kim YJ; Ahn H; Kim CS; Kim YS
    Radiat Oncol; 2020 Oct; 15(1):234. PubMed ID: 33032643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer.
    Li XA; Wang JZ; Jursinic PA; Lawton CA; Wang D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1251-7. PubMed ID: 15752907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
    Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM
    Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.